- About About
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Fact Sheet on ASA's Data Quality Act Petition to HHS Data Quality Act Briefs ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2020 State of the States Medical Cannabis Access for Pain Treatment Medical Cannabis in America
- Join Join
SAN FRANCISCO -- Ed Rosenthal, the renowned author, activist and cultivation authority whose case focused the nation’s attention on medical cannabis, is expecting an imminent decision on his appeal arguing he never should have been convicted of three marijuana felonies. The government claims he not only deserved conviction, but also appealed his one-day, time-served sentence, and is seeking to send him to prison for a minimum of five years.
WHAT: The appeal of the Rosenthal case will be decided anytime between now and the end of January by Ninth Circuit Court of Appeals. A media teleconference call will follow to explain the decision and what it means for medical cannabis patients. To be put on the conference call list, please contact Hilary McQuie at [email protected] or 510-333-8554.
WHO: Mr. Rosenthal and his family, his attorneys, and advocates with Americans for Safe Access, the largest medical marijuana rights organization nationwide, will be available for interview.
WHEN: Immediately following the announcement of the U.S. Court of Appeals for the Ninth Circuit on Mr. Rosenthal’s appeal.
WHY: Mr. Rosenthal argued that his conviction on three felony counts should be overturned because Judge Breyer erred by not letting him mount an "entrapment-by-estoppel" defense —that is, that he was misled to believe that his conduct was protected from federal prosecution through a federal statute that immunizes local officials, such as Rosenthal, who are lawfully engaged in the enforcement of a municipal ordinance relating to controlled substances.
The appeal gives additional grounds why the conviction should be overturned:
· - Federal prosecutor George Bevan committed misconduct by falsely telling the grand jury who later indicted Rosenthal that federal agencies were not aiming to shut down medical marijuana clubs;
· - Rosenthal wasn't allowed to rebut the government's claims that he grew the marijuana for profit;
· - Judge Breyer erred by instructing the jury it could not bring its "sense of justice" to bear on this case;
· - Two jurors committed misconduct by seeking the advice of an outside attorney who erroneously told them that they would get into "big trouble" if they strayed from the judge's instructions; and
- Breyer erred by refusing to exclude evidence from the Oakland warehouse based on Rosenthal's claim that the warrant lacked probable cause.
FOR MORE INFO: More information can be found at http://www.green-aid.com/ Briefs may be seen at http://www.safeaccessnow.org/downloads/Appellants_Opening_Brief.pdf and http://www.safeaccessnow.org/downloads/Appellants_Reply_Brief.pdf
# # # #